Track topics on Twitter Track topics that are important to you
Revenue at high end of range previously provided
Successful IPO completed in December 2017
Launch of SR-X in Q4, earlier than planned
Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis to advance the science of precision health, reported financial results for the fourth quarter and full year of 2017. Revenues for full year 2017 of $22.9M were at the high end of the range of $22.5-$22.9M, which was previously announced in January 2018.
“2017 was an important year for Quanterix, and I am pleased to report progress on a number of pivotal focus areas,”said Chief Executive Officer, President and Chairman, Kevin Hrusovsky. “In our first quarter as a public company, we continued to grow revenues, scale the company for future success and make inroads launching digital biomarker technologies into neurology, oncology and infectious disease application areas.”
Fourth Quarter Financial Highlights
Key financial results for the fourth quarter are shown below:
2017 and Recent Business Highlights
In conjunction with this announcement, Quanterix Corporation will host a conference call on March 14, 2018, at 4:30 p.m., EDT to discuss the Company’s financial results and business outlook. To access this call, dial (833) 686-9351 for domestic callers, or (612) 979-9890 for international callers. Please reference the following password: 5079049.
A live webcast will be accessible on the Investors section of Quanterix’ website: http://www.quanterix.com. The webcast will be available on the Company’s website for one year following completion of the call.
Financial Highlights (in thousands)
Quanterix Statement of Operations
|Q4 2017||Q4 2016||Fiscal 2017||Fiscal 2016|
|Service and other revenue||2,252||1,682||7,676||5,012|
|Cost of product revenue||2,169||1,798||7,742||6,299|
|Cost of service revenue||1,539||918||5,145||3,163|
|Cost of collaboration revenue||-||375||-||375|
|Research and development||3,927||6,801||16,304||16,993|
|Selling, General and administrative||6,046||3,600||19,688||12,466|
|Total operating expenses||13,682||13,493||48,879||39,297|
|Interest expense, net||(217||)||(286||)||(952||)||(1,298||)|
|Other income (expense), net||(73||)||(215||)||(62||)||(164||)|
|Quanterix balance sheet||12/31/17||12/31/16|
|Prepaid and other||
|Total current assets||89,252||35,243|
|Property and equipment, net||1,874||1,223|
|Other non-current assets||
|Accounts payable/accrued expenses||9,736||6,628|
|Current portion of long term debt||
|Total current liabilities||19,714||10,955|
|Preferred stock warrant liability||0||2,802|
|Deferred revenue, net of current||1,709||328|
|Long term debt||4,346||9,344|
|Other non-current liabilities||
|Redeemable convertible preferred stock||128,585|
|Total stockholders equity (deficit)||
|Total liabilities and Stockholders Equity||91,779||37,117|
Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Lexington, Massachusetts. For additional Information, please visit https://www.quanterix.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Statement on Use of Non-GAAP Financial Measures
To supplement the Company’s financial statements presented on a GAAP basis, the Company discloses non-GAAP revenue growth that excludes $1.8M in non-recurring revenue recognized in 2016 in connection with a license. Management uses this non-GAAP measure to evaluate the Company’s operating performance. Management believes that such measure is important in comparing current results with prior period results, and is useful to investors and financial analysts in assessing the Company’s operating performance. The non-GAAP financial information presented here should be considered in conjunction with, and not as a substitute for, the financial information presented in accordance with GAAP.
Reconciliation of non-GAAP Revenue Growth
|Year ended December 31,|
Non-recurring license revenue
|Non-GAAP total revenue||$22,874||$15,785||45%|
Three months ended
Non-recurring license revenue
|Non-GAAP total revenue||$6,589||$4,879||35%|
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...